Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7696MR)

This product GTTS-WQ7696MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7696MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11215MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ1505MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ7254MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ8096MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ6612MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2617MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ10663MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ2050MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW